The Relationship between the Plasma Concentration of Bepridil and Its Efficacy in the Treatment of Atrial Fibrillation in Japanese Patients
Bepridil hydrochloride is used for treatment of atrial fibrillation (AF) in Japan. We investigated the relationship between plasma concentrations of bepridil just before dosing (Cbep) and its clinical efficacy in Japanese patients (n=36) with AF. Patients were treated orally with 100, 150 or 200 mg/...
Gespeichert in:
| Veröffentlicht in: | Biological & pharmaceutical bulletin 2012/05/01, Vol.35(5), pp.672-676 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 676 |
|---|---|
| container_issue | 5 |
| container_start_page | 672 |
| container_title | Biological & pharmaceutical bulletin |
| container_volume | 35 |
| creator | Noda, Kumiko Gotoh, Yoshikazu Tanioka, Satoru Narayama, Yasuhiro Kobayashi, Michiya Iwai, Shinji Katoh, Noriyoshi Tadano, Koji |
| description | Bepridil hydrochloride is used for treatment of atrial fibrillation (AF) in Japan. We investigated the relationship between plasma concentrations of bepridil just before dosing (Cbep) and its clinical efficacy in Japanese patients (n=36) with AF. Patients were treated orally with 100, 150 or 200 mg/d bepridil. Cbep were measured with UV-HPLC. In the first 14 d, when 150, 200, 250 or 300 ng/mL was set as a boundary value, the efficacy of bepridil was significantly higher in all patients with Cbep above than below the boundary value (p |
| doi_str_mv | 10.1248/bpb.35.672 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1020188029</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1020188029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c648t-c18bcc1bddcced7848788748bb01912ebce4b90692e8b44759bc9ccdb15437ea3</originalsourceid><addsrcrecordid>eNpdkVGL1DAQx4so3nr64geQgC8idE3SpE2f5G65O08OFFmfQ5JO3SzdtCZZ5D6DX9qpvT3Bh5mBzG_-M5kpiteMrhkX6oOd7LqS67rhT4oVq0RTSs7k02JFW6bKmkl1VrxIaU8pbSivnhdnnNeqEZSuit_bHZBvMJjsx5B2fiIW8i-AQDImvg4mHQzZjMFByPEvRMaeXMIUfecHYkJHbnMiV33vnXH3xC-F2wgmH7Bmpi9y9GYg195GPyydZu6zmUyAhF3wCdH0snjWmyHBq4d4Xny_vtpuPpV3X25uNxd3pauFyqVjyjrHbNc5B12jhGoU_kZZS1nLOFgHwra0bjkoK0QjW-ta5zrLpKgaMNV58W7RneL48wgp64NPDnC0AOMxaUY5ZUpR3iL69j90Px5jwOk0E6KtVFtzidT7hXJxTClCr3E9BxPvUUrPJ9J4Il1JjSdC-M2D5NEeoHtETzdB4GYBMItLHcYw-AD_GrvUWD8Oo8YpucYCSSUGNJSfXc3QeDsrfVyU9imbH_DYysTs3QCnqeTi5upTxu1M1BCqPxFcuss</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1449389625</pqid></control><display><type>article</type><title>The Relationship between the Plasma Concentration of Bepridil and Its Efficacy in the Treatment of Atrial Fibrillation in Japanese Patients</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Noda, Kumiko ; Gotoh, Yoshikazu ; Tanioka, Satoru ; Narayama, Yasuhiro ; Kobayashi, Michiya ; Iwai, Shinji ; Katoh, Noriyoshi ; Tadano, Koji</creator><creatorcontrib>Noda, Kumiko ; Gotoh, Yoshikazu ; Tanioka, Satoru ; Narayama, Yasuhiro ; Kobayashi, Michiya ; Iwai, Shinji ; Katoh, Noriyoshi ; Tadano, Koji ; School of Pharmaceutical Sciences ; bDepartment of Pharmacy ; aDepartment of Practical Pharmacy ; cDepartment of Cardiovascular Medicine ; Health Sciences University of Hokkaido ; Sapporo City General Hospital</creatorcontrib><description>Bepridil hydrochloride is used for treatment of atrial fibrillation (AF) in Japan. We investigated the relationship between plasma concentrations of bepridil just before dosing (Cbep) and its clinical efficacy in Japanese patients (n=36) with AF. Patients were treated orally with 100, 150 or 200 mg/d bepridil. Cbep were measured with UV-HPLC. In the first 14 d, when 150, 200, 250 or 300 ng/mL was set as a boundary value, the efficacy of bepridil was significantly higher in all patients with Cbep above than below the boundary value (p<0.05). In the maintenance stage (3 months longer after starting therapy), the efficacy of bepridil was significantly higher in patients with Cbep above than below 300 ng/mL (p=0.04). The clinical efficacy of bepridil was closely related to Cbep. The target value of Cbep to obtain a clinical benefit was approximately 300 ng/mL. Monitoring Cbep should be useful in the treatment of patients with AF.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.35.672</identifier><identifier>PMID: 22687400</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Anti-Arrhythmia Agents - blood ; Anti-Arrhythmia Agents - therapeutic use ; atrial fibrillation ; Atrial Fibrillation - drug therapy ; bepridil ; Bepridil - blood ; Bepridil - therapeutic use ; bepridil plasma concentration ; Female ; Humans ; Japan ; Male ; Middle Aged ; QT prolongation ; Treatment Outcome</subject><ispartof>Biological and Pharmaceutical Bulletin, 2012/05/01, Vol.35(5), pp.672-676</ispartof><rights>2012 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c648t-c18bcc1bddcced7848788748bb01912ebce4b90692e8b44759bc9ccdb15437ea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22687400$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Noda, Kumiko</creatorcontrib><creatorcontrib>Gotoh, Yoshikazu</creatorcontrib><creatorcontrib>Tanioka, Satoru</creatorcontrib><creatorcontrib>Narayama, Yasuhiro</creatorcontrib><creatorcontrib>Kobayashi, Michiya</creatorcontrib><creatorcontrib>Iwai, Shinji</creatorcontrib><creatorcontrib>Katoh, Noriyoshi</creatorcontrib><creatorcontrib>Tadano, Koji</creatorcontrib><creatorcontrib>School of Pharmaceutical Sciences</creatorcontrib><creatorcontrib>bDepartment of Pharmacy</creatorcontrib><creatorcontrib>aDepartment of Practical Pharmacy</creatorcontrib><creatorcontrib>cDepartment of Cardiovascular Medicine</creatorcontrib><creatorcontrib>Health Sciences University of Hokkaido</creatorcontrib><creatorcontrib>Sapporo City General Hospital</creatorcontrib><title>The Relationship between the Plasma Concentration of Bepridil and Its Efficacy in the Treatment of Atrial Fibrillation in Japanese Patients</title><title>Biological & pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>Bepridil hydrochloride is used for treatment of atrial fibrillation (AF) in Japan. We investigated the relationship between plasma concentrations of bepridil just before dosing (Cbep) and its clinical efficacy in Japanese patients (n=36) with AF. Patients were treated orally with 100, 150 or 200 mg/d bepridil. Cbep were measured with UV-HPLC. In the first 14 d, when 150, 200, 250 or 300 ng/mL was set as a boundary value, the efficacy of bepridil was significantly higher in all patients with Cbep above than below the boundary value (p<0.05). In the maintenance stage (3 months longer after starting therapy), the efficacy of bepridil was significantly higher in patients with Cbep above than below 300 ng/mL (p=0.04). The clinical efficacy of bepridil was closely related to Cbep. The target value of Cbep to obtain a clinical benefit was approximately 300 ng/mL. Monitoring Cbep should be useful in the treatment of patients with AF.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Arrhythmia Agents - blood</subject><subject>Anti-Arrhythmia Agents - therapeutic use</subject><subject>atrial fibrillation</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>bepridil</subject><subject>Bepridil - blood</subject><subject>Bepridil - therapeutic use</subject><subject>bepridil plasma concentration</subject><subject>Female</subject><subject>Humans</subject><subject>Japan</subject><subject>Male</subject><subject>Middle Aged</subject><subject>QT prolongation</subject><subject>Treatment Outcome</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkVGL1DAQx4so3nr64geQgC8idE3SpE2f5G65O08OFFmfQ5JO3SzdtCZZ5D6DX9qpvT3Bh5mBzG_-M5kpiteMrhkX6oOd7LqS67rhT4oVq0RTSs7k02JFW6bKmkl1VrxIaU8pbSivnhdnnNeqEZSuit_bHZBvMJjsx5B2fiIW8i-AQDImvg4mHQzZjMFByPEvRMaeXMIUfecHYkJHbnMiV33vnXH3xC-F2wgmH7Bmpi9y9GYg195GPyydZu6zmUyAhF3wCdH0snjWmyHBq4d4Xny_vtpuPpV3X25uNxd3pauFyqVjyjrHbNc5B12jhGoU_kZZS1nLOFgHwra0bjkoK0QjW-ta5zrLpKgaMNV58W7RneL48wgp64NPDnC0AOMxaUY5ZUpR3iL69j90Px5jwOk0E6KtVFtzidT7hXJxTClCr3E9BxPvUUrPJ9J4Il1JjSdC-M2D5NEeoHtETzdB4GYBMItLHcYw-AD_GrvUWD8Oo8YpucYCSSUGNJSfXc3QeDsrfVyU9imbH_DYysTs3QCnqeTi5upTxu1M1BCqPxFcuss</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Noda, Kumiko</creator><creator>Gotoh, Yoshikazu</creator><creator>Tanioka, Satoru</creator><creator>Narayama, Yasuhiro</creator><creator>Kobayashi, Michiya</creator><creator>Iwai, Shinji</creator><creator>Katoh, Noriyoshi</creator><creator>Tadano, Koji</creator><general>The Pharmaceutical Society of Japan</general><general>Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20120501</creationdate><title>The Relationship between the Plasma Concentration of Bepridil and Its Efficacy in the Treatment of Atrial Fibrillation in Japanese Patients</title><author>Noda, Kumiko ; Gotoh, Yoshikazu ; Tanioka, Satoru ; Narayama, Yasuhiro ; Kobayashi, Michiya ; Iwai, Shinji ; Katoh, Noriyoshi ; Tadano, Koji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c648t-c18bcc1bddcced7848788748bb01912ebce4b90692e8b44759bc9ccdb15437ea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Arrhythmia Agents - blood</topic><topic>Anti-Arrhythmia Agents - therapeutic use</topic><topic>atrial fibrillation</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>bepridil</topic><topic>Bepridil - blood</topic><topic>Bepridil - therapeutic use</topic><topic>bepridil plasma concentration</topic><topic>Female</topic><topic>Humans</topic><topic>Japan</topic><topic>Male</topic><topic>Middle Aged</topic><topic>QT prolongation</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Noda, Kumiko</creatorcontrib><creatorcontrib>Gotoh, Yoshikazu</creatorcontrib><creatorcontrib>Tanioka, Satoru</creatorcontrib><creatorcontrib>Narayama, Yasuhiro</creatorcontrib><creatorcontrib>Kobayashi, Michiya</creatorcontrib><creatorcontrib>Iwai, Shinji</creatorcontrib><creatorcontrib>Katoh, Noriyoshi</creatorcontrib><creatorcontrib>Tadano, Koji</creatorcontrib><creatorcontrib>School of Pharmaceutical Sciences</creatorcontrib><creatorcontrib>bDepartment of Pharmacy</creatorcontrib><creatorcontrib>aDepartment of Practical Pharmacy</creatorcontrib><creatorcontrib>cDepartment of Cardiovascular Medicine</creatorcontrib><creatorcontrib>Health Sciences University of Hokkaido</creatorcontrib><creatorcontrib>Sapporo City General Hospital</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological & pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Noda, Kumiko</au><au>Gotoh, Yoshikazu</au><au>Tanioka, Satoru</au><au>Narayama, Yasuhiro</au><au>Kobayashi, Michiya</au><au>Iwai, Shinji</au><au>Katoh, Noriyoshi</au><au>Tadano, Koji</au><aucorp>School of Pharmaceutical Sciences</aucorp><aucorp>bDepartment of Pharmacy</aucorp><aucorp>aDepartment of Practical Pharmacy</aucorp><aucorp>cDepartment of Cardiovascular Medicine</aucorp><aucorp>Health Sciences University of Hokkaido</aucorp><aucorp>Sapporo City General Hospital</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Relationship between the Plasma Concentration of Bepridil and Its Efficacy in the Treatment of Atrial Fibrillation in Japanese Patients</atitle><jtitle>Biological & pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>35</volume><issue>5</issue><spage>672</spage><epage>676</epage><pages>672-676</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>Bepridil hydrochloride is used for treatment of atrial fibrillation (AF) in Japan. We investigated the relationship between plasma concentrations of bepridil just before dosing (Cbep) and its clinical efficacy in Japanese patients (n=36) with AF. Patients were treated orally with 100, 150 or 200 mg/d bepridil. Cbep were measured with UV-HPLC. In the first 14 d, when 150, 200, 250 or 300 ng/mL was set as a boundary value, the efficacy of bepridil was significantly higher in all patients with Cbep above than below the boundary value (p<0.05). In the maintenance stage (3 months longer after starting therapy), the efficacy of bepridil was significantly higher in patients with Cbep above than below 300 ng/mL (p=0.04). The clinical efficacy of bepridil was closely related to Cbep. The target value of Cbep to obtain a clinical benefit was approximately 300 ng/mL. Monitoring Cbep should be useful in the treatment of patients with AF.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>22687400</pmid><doi>10.1248/bpb.35.672</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-6158 |
| ispartof | Biological and Pharmaceutical Bulletin, 2012/05/01, Vol.35(5), pp.672-676 |
| issn | 0918-6158 1347-5215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1020188029 |
| source | J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry |
| subjects | Administration, Oral Adult Aged Aged, 80 and over Anti-Arrhythmia Agents - blood Anti-Arrhythmia Agents - therapeutic use atrial fibrillation Atrial Fibrillation - drug therapy bepridil Bepridil - blood Bepridil - therapeutic use bepridil plasma concentration Female Humans Japan Male Middle Aged QT prolongation Treatment Outcome |
| title | The Relationship between the Plasma Concentration of Bepridil and Its Efficacy in the Treatment of Atrial Fibrillation in Japanese Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T23%3A45%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Relationship%20between%20the%20Plasma%20Concentration%20of%20Bepridil%20and%20Its%20Efficacy%20in%20the%20Treatment%20of%20Atrial%20Fibrillation%20in%20Japanese%20Patients&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Noda,%20Kumiko&rft.aucorp=School%20of%20Pharmaceutical%20Sciences&rft.date=2012-05-01&rft.volume=35&rft.issue=5&rft.spage=672&rft.epage=676&rft.pages=672-676&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.35.672&rft_dat=%3Cproquest_cross%3E1020188029%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1449389625&rft_id=info:pmid/22687400&rfr_iscdi=true |